+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Detection of specific forms of plasminogen activator inhibitor type 1 by monoclonal antibodies



Detection of specific forms of plasminogen activator inhibitor type 1 by monoclonal antibodies



Fibrinolysis 5(2): 109-116



Monoclonal antibodies to plasminogen activator inhibitor type-1 (PAI-1) were generated and characterised for their ability to inhibit PAI-1 interaction with tissue plasminogen activator (t-PA) and urokinase (u-PA) and detection of the various forms of PAI-1 (native, complexed, and degraded) by immunoblotting. Mab17 inhibited both complex formation between PAI-1 and t-PA/u-PA and PAI-1 activity in a dose dependent manner by 90%. Mab25 was much less effective, blocking complex formation less than 30% and PAI-1 activity less than 20%. The Kds of Mab17 and Mab25 were 2.8 .times. 10-11 M and 2.6 .times. 10-10 M, respectively. Following SDS-PAGE and immunoblotting, Mab17 detected native PAI-1 only; PAI-1 in complex and the t-PA/u-PA degraded from of PAI-1 (Mr = 42000) did not react with this antibody. In contrast, Mab25 detected all three forms of PAI-1 although the affinity for the native form appeared to be greater than Mab17 or the PAI-1 polyclonal employed. Despite these differences, both monoclonal antibodies immunoprecipitated native and degraded PAI-1 equally as well. These results suggest that the epitope of Mab17 is associated with the reactive site of PAI-1 and that this region is either missing or not accessible in the cleaved form or in complex.

(PDF emailed within 0-6 h: $19.90)

Accession: 007191340

Download citation: RISBibTeXText

DOI: 10.1016/0268-9499(91)90052-6



Related references

Production of monoclonal antibodies against the plasminogen activator inhibitor-1/tissue-type plasminogen activator complex. Fibrinolysis 8(SUPPL 1): 3, 1994

Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Annals of the New York Academy of Sciences 667: 428-430, 1992

Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator and urokinase-type plasminogen activator. Brakman, P, Kluft, C Annals of the New York Academy of Sciences; Plasminogen activation in fibrinolysis, in tissue remodeling, and in development: 428-430, 1992

On the reversible interaction of recombinant plasminogen activator inhibitor 1 rpai 1 with different molecular forms of tissue type plasminogen activator t pa or urokinase type plasminogen activator u pa. Fibrinolysis 4(SUPPL 3): 165, 1990

Reaction of different forms of plasminogen activator inhibitor pai 1 with monoclonal antibodies. Fibrinolysis 4(SUPPL 3): 42, 1990

Reaction of different forms of plasminogen activator inhibitor pa 1 with monoclonal antibodies using a dot immunobinding assay. British Journal of Haematology 76(SUPPL 1): 35, 1990

Monoclonal antibodies against a recombinant form of plasminogen activator inhibitor-1: Effects on tissue plasminogen activator neutralizing and vitronectin binding properties. Fibrinolysis 7(6): 373-378, 1993

Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells: Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. European Journal of Biochemistry 233(2): 514-519, 1995

Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thrombosis and Haemostasis 53(1): 122-125, 1985

Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncology Reports 17(5): 1259-1268, 2007

Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. Thrombosis Research 62(4): 275-285, 1991

Transient and cell-specific expression of tissue-type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotropin-induced ovulation. European Journal of Biochemistry 214(1): 147-156, 1993

Gonadotropin induced transient and cell specific expression of tissue type plasminogen activator and plasminogen activator inhibitor type 1 leads to a controlled and directed proteolysis during ovulation. Fibrinolysis 6(SUPPL 4): 151-155, 1992

Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression. Molecular & Cellular Endocrinology 133(2): 109-116, Oct 20, 1997